Patients involved in GLP-1 lawsuits allege that these drugs caused debilitating health effects linked to delayed gastric emptying, intestinal obstruction, chronic vomiting, severe abdominal pain, dehydration, malnutrition, and sudden vision loss
Personalizing Your Supplement Plan with PlexusDx Genetic Testing The PlexusDx Precision Peptide Genetic Test analyzes FTO (rs9939609), and MC4R (rs17782313) variants that relate to GLP-1 and related signaling pathways
long-term use has shown consistent weight loss
As monotherapy , a multicentre, randomised, double-blind, placebo-controlled and active-controlled Phase 2 dose-finding trial enrolled 706 adults with overweight or obesity (without diabetes) to once-weekly subcutaneous cagrilintide across doses of 0.3 to 4.5 mg over 26 weeks